Ö. Türeci

1.6k total citations · 1 hit paper
10 papers, 1.3k citations indexed

About

Ö. Türeci is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, Ö. Türeci has authored 10 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Molecular Biology, 4 papers in Immunology and 3 papers in Oncology. Recurrent topics in Ö. Türeci's work include Immunotherapy and Immune Responses (4 papers), Barrier Structure and Function Studies (3 papers) and Pancreatic and Hepatic Oncology Research (2 papers). Ö. Türeci is often cited by papers focused on Immunotherapy and Immune Responses (4 papers), Barrier Structure and Function Studies (3 papers) and Pancreatic and Hepatic Oncology Research (2 papers). Ö. Türeci collaborates with scholars based in Germany, Netherlands and United States. Ö. Türeci's co-authors include Uğur Şahin, Michael Pfreundschuh, Frank Stenner, Guorong Luo, Tanja Johannes, Rudolf Schmits, Holger Schmitt, B. Cochlovius, Michael Koslowski and Gerhard Seitz and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Oncogene and Annals of Oncology.

In The Last Decade

Ö. Türeci

10 papers receiving 1.3k citations

Hit Papers

Human neoplasms elicit multiple specific immune responses... 1995 2026 2005 2015 1995 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Human neoplasms elicit multiple specific immune responses in the autologous host.
    1995 896 citations Uğur Şahin, Ö. Türeci et al. Proceedings of the National Academy of Sciences profile →

Peers

Ö. Türeci
Xiaoqiang Kang United States
Jean-Michel Vernes United States
Jan L. Fisher United States
Anne Girling United Kingdom
B. Cochlovius Germany
Debora Pezzuolo Italy
Sonja Offner Germany
Yannick Guilloux France
Berris van Kessel Netherlands
Karen Sisley United Kingdom
Xiaoqiang Kang United States
Ö. Türeci
Citations per year, relative to Ö. Türeci Ö. Türeci (= 1×) peers Xiaoqiang Kang

Countries citing papers authored by Ö. Türeci

Since Specialization
Citations

This map shows the geographic impact of Ö. Türeci's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ö. Türeci with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ö. Türeci more than expected).

Fields of papers citing papers by Ö. Türeci

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ö. Türeci. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ö. Türeci. The network helps show where Ö. Türeci may publish in the future.

Co-authorship network of co-authors of Ö. Türeci

This figure shows the co-authorship network connecting the top 25 collaborators of Ö. Türeci. A scholar is included among the top collaborators of Ö. Türeci based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ö. Türeci. Ö. Türeci is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Haanen, J.B.A.G., Andréas Mackensen, Christian Koenecke, et al.. (2021). LBA1 BNT211: A phase I/II trial to evaluate safety and efficacy of CLDN6 CAR-T cells and CARVac-mediated in vivo expansion in patients with CLDN6+ advanced solid tumors. Annals of Oncology. 32. S1392–S1392. 7 indexed citations
2.
3.
Heinz, C., Rita Mitnacht‐Kraus, Maria M. Kreuzberg, et al.. (2017). Preclinical evaluation of the anti-CLDN18.2 antibody, IMAB362, in pancreatic carcinoma. Annals of Oncology. 28. v125–v126. 6 indexed citations
4.
Kreuzberg, Maria M., Rita Mitnacht‐Kraus, Uğur Şahin, & Ö. Türeci. (2017). Preclinical characterization of IMAB362-vcMMAE, an anti-CLDN18.2 antibody–drug conjugate. Annals of Oncology. 28. v126–v126. 7 indexed citations
5.
Mitnacht‐Kraus, Rita, et al.. (2017). Preclinical characterization of IMAB362 for the treatment of gastric carcinoma. Annals of Oncology. 28. v126–v126. 25 indexed citations
6.
Koslowski, Michael, Ulrich Luxemburger, Ö. Türeci, & Uğur Şahin. (2010). Tumor-associated CpG demethylation augments hypoxia-induced effects by positive autoregulation of HIF-1α. Oncogene. 30(7). 876–882. 67 indexed citations
7.
Şahin, Uğur, Michael Koslowski, Ö. Türeci, et al.. (2000). Expression of cancer testis genes in human brain tumors.. PubMed. 6(10). 3916–22. 102 indexed citations
8.
Türeci, Ö., Uğur Şahin, Michael Koslowski, et al.. (1996). The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40.. PubMed. 56(20). 4766–72. 206 indexed citations
9.
Şahin, Uğur, Ö. Türeci, Holger Schmitt, et al.. (1995). Human neoplasms elicit multiple specific immune responses in the autologous host.. Proceedings of the National Academy of Sciences. 92(25). 11810–11813. 896 indexed citations breakdown →
10.
Türeci, Ö., Hans Fischer, Pierre Lagoda, & O.-G. Issinger. (1990). Characterization of Human Glioblastoma Cell Lines in vitro and their Xenografts in Nude Mice by DNA Fingerprinting. Oncology Research and Treatment. 13(4). 305–308. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xiaoqiang Kang Breakdown of academic impact, for papers by Jean-Michel Vernes Breakdown of academic impact, for papers by Jan L. Fisher Breakdown of academic impact, for papers by Anne Girling Breakdown of academic impact, for papers by B. Cochlovius Breakdown of academic impact, for papers by Debora Pezzuolo Breakdown of academic impact, for papers by Sonja Offner Breakdown of academic impact, for papers by Yannick Guilloux Breakdown of academic impact, for papers by Berris van Kessel Breakdown of academic impact, for papers by Karen Sisley
Rankless by CCL
2026